Skip to main content
. 2021 Dec 10;9(2):ofab629. doi: 10.1093/ofid/ofab629

Table 3.

DRA-OPAT Participants by Program Completion

Cohort Completed DRA-OPAT Did Not Complete Program
N 16 19
Age, years (median, IQI) 35 (28–53.3) 40 (34–49)
Male, N (%) 9 (56.3) 10 (52.6)
Race, non-white 1 (6.3) 5 (26.3)
Cocaine use 1 (6.3) 1 (5.3)
Opioid use 15 (93.8) 13 (68.4)
Polysubstance use 8 (50) 14 (73.7)
Stimulant use 8 (50) 15 (78.9)
Medication for opioid use disordera 14 (87.5) 8 (42.1)
Homelessa 12 (75) 8 (42.1)
Insured 1 (6.3) 6 (31.6)
Charlson comorbidity index 32 (12.5) 20 (12–33)
HIV 0 (0) 0 (0)
Hepatitis C 4 (25) 5 (26.3)
Cerebrovascular disease 1 (6.3) 2 (10.5)
Congestive heart failure 0 (0) 4 (21.1)
Diabetes mellitus 2 (12.5) 5 (26.3)
Hepatic disease 5 (31.3) 7 (36.8)
Chronic pulmonary disease 6 (37.5) 6 (31.6)
Kidney disease 2 (12.5) 2 (10.5)
Endocarditis 7 (43.8) 7 (36.8)
Osteoarticular infection 6 (37.5) 8 (42.1)
Skin/soft tissue infection 12 (75) 8 (42.1)
Vertebral abscess/discitis/osteomyelitis 6 (37.5) 4 (21.1)
Staphylococcus aureus bacteremia 8 (50) 9 (47.4)
Bone or joint debridement 7 (43.8) 5 (26.3)
Cardiac valve replacement 0 (0) 0 (0)
Soft tissue debridement 6 (37.5) 7 (36.8)
Spinal debridement 2 (12.5) 1 (5.3)
Hospital length of stay, days (median, IQI)a 13.5 (10.6–18.5) 9.1 (7.7–13.4)
Days at program facilitya 24 (19.5–38) 4 (2–9)
30-day readmission 2 (12.5) 2 (10.5)
90-day readmission 5 (31.3) 4 (21.1)
Mortality, 30-day all-cause 0 (0) 0 (0)
Mortality, 1-year 0 (0) 0 (0)
Positive toxicology screen during program 0 (0) 2 (10.5)
PICC line abuse 0 (0) 2 (10.5)
Adverse event during program treatment 3 (18.8) 4 (21.1)

Abbreviations: DRA-OPAT, drug recovery assistance and parenteral antibiotic therapy; HIV, human immunodeficiency virus; IQI, 25%–75% interquartile interval; PICC, peripherally inserted central venous catheter.

Significant at P < .05.